Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Short-term Investments (2016 - 2020)

Historic Short-term Investments for Immucell (ICCC) over the last 10 years, with Q4 2020 value amounting to $996495.0.

  • Immucell's Short-term Investments fell 5983.09% to $996495.0 in Q4 2020 from the same period last year, while for Dec 2020 it was $996495.0, marking a year-over-year decrease of 5983.09%. This contributed to the annual value of $996495.0 for FY2020, which is 5983.09% down from last year.
  • Per Immucell's latest filing, its Short-term Investments stood at $996495.0 for Q4 2020, which was down 5983.09% from $2.0 million recorded in Q3 2020.
  • In the past 5 years, Immucell's Short-term Investments ranged from a high of $8.7 million in Q2 2019 and a low of $489582.0 during Q2 2017
  • Moreover, its 4-year median value for Short-term Investments was $3.0 million (2017), whereas its average is $3.9 million.
  • Its Short-term Investments has fluctuated over the past 5 years, first surged by 24206.9% in 2016, then crashed by 9268.84% in 2017.
  • Quarter analysis of 4 years shows Immucell's Short-term Investments stood at $5.5 million in 2016, then crashed by 91.06% to $489582.0 in 2017, then surged by 406.71% to $2.5 million in 2019, then crashed by 59.83% to $996495.0 in 2020.
  • Its Short-term Investments was $996495.0 in Q4 2020, compared to $2.0 million in Q3 2020 and $2.0 million in Q2 2020.